1. No category

Barentsz
2-4-2011
Advances in Prostate
MR imaging
Learning
LearningObjectives
Objectives
• to show the potential of
new MR
MRII developments in PCa
Jelle Barentsz
Prostate MR Center of Excellence
Department of Radiology
Radboud University Nijmegen Medicaal Center
The Netherlands
• to illustrate this from a clinical
(radiation oncology)
oncology) perspective
j.barentsz@rad.umcn.nl
Multi-parametic
Learning ObjectivesMRI
T2WI MRI: anatomy
1. High resolution T2
T2WI:
WI: anatomy
2. Diffusion Weighted Imaging: function
3. Hydrogen MR
MR--Spectroscopy: function
4. Dynamic Contrast Enhanced: function
1
Barentsz
2-4-2011
c. Villiers
MRI: high soft tissue contrast
CT Image
Delineation of CTV
Additional Use of MRI
Delineation of CTV:
CT > MRI
MR Image
MR-anatomy of PCa
• Smaller CTV (6.5%(6.5%-34%)
• Inter
Inter--observer variability ↓ (~63%) at:
-
Apex :
↓↓↓↓
Base :
↓↓
SV :
↓
Mid--gland : Mid
Roach IJROPB 1996,
Rash IJROPB 1999,
Villiers,, Strahlenther Onko 2006
Villiers
PCa, hematoma, fibrosis, prostatitis: low SI
2
Barentsz
2-4-2011
Patient 57 y, PSA 7; TRUS Bx: negative
T2WI: PCa anatomy
Your diagnosis?
1.
2.
3.
4.
normal
BPH
prostatitis
ventral TZ tumor
T2WI: Local Staging
T2WI: PCa anatomy
•
•
•
•
BPH: organised chaos
“Erased Charcoal drawing sign”
prostatectomy vs radiotherapy
decrease R+
nerve sparing
local therapy
3T ERC:
se 87% sp 96%
Futterer, Invest Radiol 2006, Heijmink, Radiology 2007
3
Barentsz
2-4-2011
Multi-parametric MRI: DWI
DWI: ADC-value versus Gleason score
Pearson
Correlation
Organised galandular tissue
Tightly packed cellular tissue
r = 0.73
p < 0.01
DWI: PCa restricted H2O movement
Specificity, aggression!
DWI: ADC-value vs Gleason score
Hambrock,, Radiology, in press
Hambrock
Alvares,, Radiology, in press
Alvares
Multi-parametric MRI: DCE
DCE MRI: PCa increased vascular permeability
Sensitivity!!
Sensitivity
4
Barentsz
2-4-2011
MR Spectroscopy
MR Spectroscopy
Metabolite ratio Cho + Cr
Cit
↑
Creatine
Citrate
0.37 / 0.64
For Ferrari drivers only?
MR Spectroscopy
Clinical Problems
•
PSA:: non specific marker :
PSA
>4 ng
ng/L:
/L: sens.:
sens.: 80%, spec
spec.:
.: 36%
•
DRE is not sensitive
- sens
sens.:
.: 37%
37%,, spec
spec.:
.: 91%
You need EXPERIENCE how to drive
Djavan J Urol (2001); Roehl J Urol (2002); Pepe Urol (2007), Schroeder JNCI (1998)
5
Barentsz
2-4-2011
Problems: TRUS Bx
•
Clinically insignificant
cancers are identified by
chance
•
Important cancers are
incorrectly classified as
unimportant or are missed
•
36- 46% undergrading of
36Gleason score
Be aware!
EU Urologists are getting there
Sciarra, European Urology 2011
Multi-modality MRI:
MR-guided biopsy
Intraprostatic Localization Accuracy
Accuracy::
T2
T2--w :
70%
Jager AJR 1996; Scheidler Radiol 1999
DWI--MRI:
DWI
86%
Haider AJR 2007; Miao Eur J Rad 2007
H-MRS:
81%
Futterer Radiol 2006, Reinsberg AJR 2007
DCE-- MRI:
DCE
85%
Ito Br J Radiol 2003, Futterer Radiol 2006
Gleason score 4+3
6
Barentsz
2-4-2011
3T MR-biopsy (n=68)
• After ≥2 - biopsies: TRUS is + in 5-19%
• MR-guided biopsy of TSR: + in 59% (40/68)
What is beyond
theObjectives
horizon?
Learning
1. Improvement of mpmp-MR directed
biopsy techniques
2. Active Surveillance, Screening
• with MR ~ 4 cores instead of ~ 12
3. Will mpmp-MRI replace Gleason?
• 57% anterior tumors
4. Focal therapy
• 93% (37/40) clinically significant tumors
nano--particles + DWI
5. Nodes:
Nodes: nano
Hambrock, J Urol 2010
What is beyond
theObjectives
horizon?
Learning
What is beyond
theObjectives
horizon?
Learning
1. Improvement of mpmp-MR directed
biopsy techniques
1. Improvement of mpmp-MR directed
biopsy techniques
2. Active Surveillance, Screening
2. Active Surveillance, Screening
3. Will mpmp-MRI replace Gleason?
3. Will mpMRI replace Gleason
Gleason?
?
4. Focal therapy
4. Focal therapy
5. Nodes: nano
nano--particles + DWI
5. Nodes:
Nodes: nanonano-particles + DWI
7
Barentsz
2-4-2011
Biopsy with TRUS - mp-MRI fusion
Hit the most aggressive lesion
with TRUS – MR (ADCmap) fusion
Learning
FutureObjectives
Potential
MR-robot
First, diagnostic session
Case: 59 y.o., PSA 10, 3x negative TRUS sessions
T2
T2--weighted
• MR
MR--robot with MR guided remote control
DWI
DCE
TSR 2
8
Barentsz
2-4-2011
9
Barentsz
2-4-2011
What is beyond
theObjectives
horizon?
Learning
Perform biopsy
1. Improvement of mpmp-MR
MR--directed
biopsy techniques
2. Active Surveillance, Screening
Histopathology
Gleason 4+3
3. Will mpmp-MRI replace Gleason?
4. Focal therapy
5. Nodes:
Nodes: nanonano-particles + DWI
PZ PCa with focal
“hot spot” (Gl 4+3
4+3))
10
Barentsz
2-4-2011
Focal therapy
Focal therapy
- Focal laser ablation
- HDR Brachytherapy / DIL IMRT
DWI with b values 0, 50, 600
ADC map showing restricted
diffusion
c. J. Feller, Palm Springs USA
Focal therapy
Focal therapy
Prostate Capsule
Target Area
Thermal Ablation
Damage Estimate
Laser Doses
Treatment #1
177s @ 8.00W
Visible Damage
10mm by 12mm
Animation – not in real-time
Treatment temperature map
Irreversible damage estimate
c. J. Feller, Palm Springs USA
T2 Pre-treatment Image
Irreversible damage estimate
Axial Images
Post-treatment MRI
Laser Fiber Trajectory
c. J. Feller, Palm Springs USA
11
Barentsz
2-4-2011
Focal therapy
Marker fusion CT-MRI
Huisman Radiology 2005
- Focal laser ablation
- HDR Brachytherapy / DIL IMRT
inaccuracy < 1 mm
at periphery of prostate
f-MR-based DIL IMRT Planning
What is beyond
theObjectives
horizon?
Learning
1. Improvement of mpmp-MR
MR--directed
biopsy techniques
2. Active Surveillance, Screening
3. Will mpmp-MRI replace Gleason?
4. Focal therapy
5. Nodes: nano
nano--particles + DWI
IMRT: Partial boost to 90 Gy
van Lin IJROBP 2006
12
Barentsz
2-4-2011
Pathway of spread
SVI
Detecting Nodal metastasis
in PCa
• Imaging (CT, MRI etc)
- Less invasive
- Inaccurate size
criterion
MRL detected in 41% patients
Positive nodes outside routine PLND
• Surgery (PLND)
- Invasive, costly
- Limited in coverage
Heesakkers et al Radiology 2009
Vincent van Gogh
Sorrowing old man
Dutch study: 13 centres
Fe
Fe--nanoparticles
(20 nm)
Ferumoxtran--10
Ferumoxtran
(Combidex/Sinerem))
(Combidex/Sinerem
Patient--toPatient
to-patient correlation
CT
accuracy
86%
specificity
97%
sensitivity
34%
NPV
89%
(n=375)
→
→
→
→
MRL
91%
91%
93%
93%
93%
93%
97%
97%
Probability of correct diagnosis:
diagnosis:
MRL
91%
PLND + CT 89%
Heesakkers et al Lancet Oncology 2008
13
Barentsz
2-4-2011
Meijer, IJROPB in preparation
Post Px recurrence: MRL
Nodal Roach Formula: Low PPV
PSA ≥0.2
≥0.2 ng/ml
ng/ml 6 w. postop. + 1 higher value, or a single PSA ≥0.5 ng/ml;
ng/ml;
no bone metastases
•
•
•
72% (47/65) ≥1 ⊕ node, 6/275 nodes >1 cm
62%
62% had ≥1
≥1 ⊕ node with low PSA (<1.0
<1.0))
77% and 61% ≥1 ⊕ node in regions not in CTV for elective
pelvic irradiation by the RTOG
4. Many nodes are not in CTV
Deserno, IJROPB 2010
IMRT planning
IJROPB 2010
• Accurate mapping of
positive MRL nodes
for IMRT has the
potential:
- to reduce toxicity in
normal tissue
- allows higher doses
on the positive nodes
14
Barentsz
2-4-2011
Case
• 60 yr;
yr; initial PSA 6; Gleason 4+3
• Dec 2005: Da Vinci Px
Px:: T3B N1 Mx R+
• Feb 2006: PSA 0.22
What treatment:
treatment: hormonal palliative
whole pelvic radiation
para--aortic nodes
para
nodes?
?
March 2005 Combidex/Sinerem MRI
Case
Case 1
• March 2005 Combidex/Sinerem MRI:
• 6 positive pelvic nodes
4D--IG
IG--IMRT:
IMRT: dose painting
→ ADT + 4D
c M Dattoli
15
Barentsz
2-4-2011
But
Case
• PSA
PSA:: Nov 06:
Apr 07:
0.0006
0.003
Due to approval
problems,
development
of Combidex
is discontinued
July 07: Stop ADT
• PSA
PSA::
Aug 07:
March 08:
March 09:
March 10:
<0.01*
<0.003
<0.003
<0.01*
Combidex/Sinerem MRI November 2009
But there is hope: DWI? Ferumoxytol? P904?
DWI helps to find
bone and nodal metas
Future: ferumoxytol
ferumoxytol:: WIP
24 hrs post Combidex 24 hrs post ferumoxytol
c. S Bravo, Orlando
CTA
post ferumoxytol
post ferumoxytol + Gd
16
Barentsz
2-4-2011
PSA Relapse: Imaging Protocol
• Bone:
DWI MRI of pelvis & spine
• Nodes:
Nanoparticle MRI (n.a.)
DWI MRI of pelvis & spine
• Local:
DCE
DCE-- and DWI MRI
Post-Brachy, PSA recurrence
bone + X: se 63% sp 64%
Post-Brachy, PSALearning
recurrence
(1.8)
Objectives
Post-Brachy, PSA recurrence
MRI: se 100% sp 88%
Spine and pelvis is enough
Lecouvet JCO 2007
17
Barentsz
2-4-2011
Meijer, IJROPB in preparation
PSA Relapse: Imaging Protocol
• Bone:
DWI MRI of pelvis & spine
• Nodes:
Nanoparticle MRI (n.a.)
DWI MRI of pelvis & spine
• Local:
DCE- and DWI MRI
Future: MRL or 11C Choline PET/CT?
Post Px recurrence
recurrence:: MRL
Stephenson nomogram accurately predicted
⊕ MRL result →can be used to identify patients
for pelvic radiation
but
We need better imaging to decrease the CTV
Meijer, IJROPB 2010
Future: MRL or 11C Choline PET/CT?
MRL
• 151 positive nodes in 23/29 patients
mean size 4.9 mm*
11C
Choline PET/CT
• 34 positive nodes in 13/29 patients
mean size 8.4 mm*
* p<0.001 more and smaller nodes detected
18
Barentsz
2-4-2011
Negative PET/CT:
post-RP (T3b N0 M0)
USPIO--MRI
USPIO
post Px
Choline PET/CT
DCE MRI!
PSA Relapse: Imaging Protocol
• Bone:
DWI MRI of pelvis & spine
• Nodes:
Nanoparticle MRI (n.a.)
DWI MRI of pelvis & spine
• Local:
DCE- and DWI MRI
Local post radiotherapy
recurrence: DCEDCE- MRI
T2
T2--w
DCE Ktrans
19
Barentsz
2-4-2011
Take home messages
• MRI is the best technique to show the
prostate and its tumor localization and
aggression
• MRI is a superior technique in showing
small nodal and bone metastates
• integration of Rth and MRI still needs a
lot of research but offers great potential
Thank you for your attention
Bomers, Debats, Fütterer,
Hambrock, Huisman,
Heijmink, Heerschap,
Hoeks, Scheenen, Yakar.
Hulsbergen, van Lin,
Hulsbergen,
van Oort, Witjes, Dattoli
20